Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been given an average recommendation of “Moderate Buy” by the eight research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $13.70.

A number of equities research analysts have issued reports on the company. HC Wainwright cut their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Finally, B. Riley Financial restated a “buy” rating and set a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $5.43 on Monday. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $5.51 and its 200-day simple moving average is $6.44. The stock has a market capitalization of $328.30 million, a price-to-earnings ratio of -1.17 and a beta of 0.64. Vanda Pharmaceuticals has a twelve month low of $4.27 and a twelve month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The company had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. Equities research analysts forecast that Vanda Pharmaceuticals will post -3 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VNDA. Quantbot Technologies LP acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $29,000. Russell Investments Group Ltd. boosted its position in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 5,328 shares during the period. Legal & General Group Plc acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth approximately $34,000. Allworth Financial LP bought a new position in Vanda Pharmaceuticals in the 2nd quarter worth approximately $43,000. Finally, Quarry LP bought a new position in Vanda Pharmaceuticals in the 3rd quarter worth approximately $53,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.